bioAffinity Technologies specializes in AI-driven, flow cytometry-based diagnostics targeting early lung cancer detection through its flagship CyPath® Lung test. Since initiating revenue generation in 2024, the company demonstrated sequential growth but at mounting losses and negative operating cash flows, straining liquidity. A large-scale clinical trial launched in early 2026 aims to validate CyPath® Lung further as the company expands commercial efforts via its CAP-accredited and CLIA-certified laboratory platform. Despite technological moat and scientific credibility, bioAffinity faces substantial execution risks including capital constraints, regulatory hurdles, and competitive pressures from larger players. Monitoring progress on reimbursement, trial enrollment milestones, and financing activities will be critical to assessing sustainability.